Galapagos Nv

Janssen Pharmaceutica Nv

Burritt, Andrew

Martin James Inglis Andrews

Mark Stuart Chambers

Wolfgang Schmidt

Kim Louise Hirst

Juha Andrew Clase

Paul John Edwards

Sébastien Laurent Xavier Martina

Grégory Louis Joseph Bar

Angus MacLeod

Gregory Bar

Steven Emiel Van Der Plas

Hans Kelgtermans

Sébastien Jean Jacques Cédric Dropsit Montovert

Veronique Birault

Philip Huxley

Clifford John Harris

Reginald Christophe Xavier Brys

Giovanni Alessandro Tricarico

Xueliang Tao

Olga Raquel Pinto Santos Oliveira Roussel

Friedrich Erich Karl Kroll

Andrew Burritt

Hervé Van De Poël

Brigitte Allart

Sébastien Jean-Jacques Cédric Dropsit-Montovert

Paul Edwards

The present invention discloses compounds according to Formula I: wherein Ris as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.

Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis

The present invention discloses compounds according to Formula I:  wherein Ris as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.

Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel fused pyrazine compounds are disclosed that have a formula represented by the following: with Z, R, R, Rand Ras defined in the written description. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Novel [1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases

Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.

Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazolopyridine compounds are disclosed that have a formula represented by the following:  The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.

Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following:  The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazo[-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Growing community of inventors

Mechelen, Belgium

Martin James Inglis Andrews